Summary of COVID-19 levilimab studies

1. Lomakin et al., The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study

206 patient levilimab late treatment RCT: 70% lower ICU admission (p=0.08) and 65% greater improvement (p<0.0001).
RCT 206 severe COVID-19 patients not requiring mechanical ventilation, showing higher sustained clinical improvement and lower ICU admission with levilimab. There was no difference in mortality.
Sep 2021, Inflammation Research, https://link.springer.com/10.1007/s00011-021-01507-5, https://c19p.org/lomakin

Submit Corrections or Updates

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0